Muna Therapeutics appoints Dr. Donald Nicholson as Independent Chair of Board of Directors

Industry leader with expertise in building successful biotechnology companies

Copenhagen, Denmark and Boston, US 13th September 2021 – Muna Therapeutics (“Muna”), pioneering the development of first-in-class small molecule therapeutics for neurodegenerative diseases, today announced the appointment of Dr. Donald Nicholson, as independent Chair of its Board of Directors.


Read more…


By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...